Better Use of Nicotine Replacement Therapies Can Help Smokers Quit

MedicalResearch.com Interview with:

Dr Nicola Lindson PhD CPsycholCochrane Tobacco Addiction Group (TAG) Managing Editor & Senior Researcher Nuffield Department of Primary Care Health Sciences,University of Oxford 

Dr. Lindson

Dr Nicola Lindson PhD CPsychol
Cochrane Tobacco Addiction Group (TAG) Managing Editor & Senior Researcher
Nuffield Department of Primary Care Health Sciences,
University of Oxford
 

MedicalResearch.com: What is the background for this study? What are the main findings? 

Response: People have been using nicotine replacement therapy, otherwise known as NRT, to quit smoking for more than 20 years. NRT is available in a range of forms: skin patches, chewing gum, nasal and oral sprays, inhalators, and lozenges. We have good evidence that it is safe and that it helps more people to quit than trying to stop smoking using no medication.

We carried out a systematic review to try and find out what the best ways are to use NRT to maximise a person’s chances of quitting successfully. We did this by looking at studies that compared at least two different types of NRT use, such as higher versus lower doses, or longer versus shorter use.

The takeaway message from the review is that using more nicotine (in the form of nicotine replacement therapy, ) to aid quitting can help more people to stop smoking in the long-term. There is high quality evidence that using two forms of nicotine replacement at the same time – a patch as well as a faster-acting form such as gum – increases chances of quitting, and evidence also suggests that starting to use nicotine replacement before the day you give up cigarettes can help more people quit than beginning use on the day you stop.

There is no evidence that using more nicotine replacement is harmful when used as directed. Continue reading

Exercise Prevents Falls

MedicalResearch.com Interview with:
"DSC08418" by Debs (\xf2\u203f\xf3)\u266a is licensed under CC BY 2.0. To view a copy of this license, visit: https://creativecommons.org/licenses/by/2.0Cathie Sherrington FAHMS
Professor, NHMRC Senior Research Fellow
Institute for Musculoskeletal Health
The University of Sydney

MedicalResearch.com: What is the background for this study? What types of exercise were tested or indicated?

Response: Falls are a very common problem with at least one in three people aged 60+ falling each year. This review included all types of exercises delivered to people aged 60+ in the general community i.e., not those living in supported accommodation and not among people with particular health conditions such as a stroke or Parkinson’s disease.

Continue reading

Does Methylphenidate (Ritalin) Cause Psychotic Symptoms in ADHD ?

MedicalResearch.com Interview with:
Erica Ramstad Pre-graduate research student hos Psychiatric Research Unit, Department of Children and Youth Psychiatry Copenhagen Area DenmarkErica Ramstad MD
Physician, Psychiatric Research Unit
Child and Adolescent Psychiatric Department
Region Zealand, Denmark

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Methylphenidate is the first-choice drug treatment of attention-deficit/hyperactivity disorder (ADHD), which affects around 5.3% children and adolescents worldwide. For 50 years, psychotic symptoms have occasionally been reported in relation to methylphenidate treatment – however, it has not been established whether the symptoms occur as an adverse event to the treatment.

We performed a systematic review on the topic. The data we included in our study are a subset and an update of data from the most comprehensive systematic reviews of methylphenidate to date. Despite this, we could not confirm or refute whether psychotic symptoms occur as an adverse event. The data are too sparse, and the quality of evidence is too low.

MedicalResearch.com: What should readers take away from your report?

Response: Methylphenidate treatment may cause psychotic symptoms in 1.1% to 2.5% of children and adolescents with ADHD. Physicians, patients and their caregivers should be aware of this possible adverse event. However, concerns about this rare possible adverse event should of course be balanced against the potential beneficial effects of methylphenidate on ADHD symptoms, general behaviour and quality of life.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: In future studies, psychotic symptoms should be assessed concurrently with other possible adverse events and beneficial effects of methylphenidate treatment of ADHD in children and adolescents. Psychotic symptoms, the severity and implication for the child/adolescent ought to be assessed by clinical interviews. Of course, high-quality, long-term randomized placebo-controlled trials are on the top of the wish list, but long-term placebo administration is ethically questionable, and therefore also non-randomized studies may be of great importance.

MedicalResearch.com: Is there anything else you would like to add?

Response: This study was funded by the Region Zealand Research Foundation, Denmark; Psychiatric Research Unit, Region Zealand, Slagelse, Denmark; the Copenhagen Trial Unit, the Centre for Clinical Intervention Research, Copenhagen University Hospital, Denmark. For conflicts of interest please see the original article (p. 16).

Citation: Scandinavian Journal of Child and Adolescent Psychiatry and Psychology. VOLUME 6 , ISSUE 1 , ISSN (Online) 2245-8875, DOI: 10.21307/sjcapp-2018-003, July 2018 © 2018.

Aug 25, 2018 @ 6:13 pm

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Cochrane Reviews Efficacy of Vaccination To Prevent Flu In Healthy Adults

MedicalResearch.com Interview with:
“#influenza” by J.S. Zolliker is licensed under CC BY 2.0Dr. Vittorio Demicheli

Servizio Regionale di Riferimento per l’Epidemiologia
SSEpi-SeREMI, Azienda Sanitaria Locale ASL AL
Alessandria, Piemonte, Italy

MedicalResearch.com: What is the background for this study? What are the main findings? 

Response: The consequences of influenza in adults are mainly time off work. Only vaccination of pregnant women is recommended internationally, while mass vaccination of healthy adults is still matter of debate.

The aim of this Cochrane Review is to assist informed decision making summarizing research that looks at the effects of immunizing healthy adults with influenza vaccines during influenza seasons.

The review process found 52 clinical trials of over 80,000 adults. Only around 15% of the included studies were well designed and conducted. We focused on reporting of results from 25 studies that looked at inactivated vaccines. Injected influenza vaccines probably have a small protective effect against influenza and influenza-like illness (ILI_ (moderate-certainty evidence), as 71 people would need to be vaccinated to avoid one influenza case, and 29 would need to be vaccinated to avoid one case of ILI. Vaccination may have little or no appreciable effect on hospitalizations (low-certainty evidence) or number of working days lost. Continue reading